The U.S. Food and Drug Administration (FDA) has approved the combination of two oral therapies, Venclexta (venetoclax) and Calquence (acalabrutinib), for previously untreated adults with…
Blood cancer
Enrollment is now complete for an early clinical study assessing the safety and tolerability of SENTI-202, Senti Biosciences’ cell therapy candidate for adults with…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to an experimental treatment from Imviva Biotech that’s being tested in people…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to QTX-2101, an oral formulation of an approved chemotherapy drug, as a potential treatment…
The U.S. Food and Drug Administration (FDA) has granted breakthrough designation to soficabtagene geleucel (sofi-cel), a cell therapy designed to treat relapsed or refractory T-cell…
All four adults with hard-to-treat acute myeloid leukemia (AML) who received treatment with a combination of Venclexta (venetoclax) and AB Science‘s experimental therapy AB8939…
A Phase 3 clinical trial testing the experimental cancer vaccine galinpepimut-S (GPS) in people with acute myeloid leukemia (AML), a type of blood cancer,…
Olverembatinib (HQP1351), used in combination with low-intensity chemotherapy, has shown encouraging therapeutic potential — along with a favorable safety profile — in individuals with newly…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SENTI-202, Senti Biosciences‘ experimental cell therapy being developed…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the experimental medicine CLN-049, which is being developed as a potential treatment…
